West-Ward Recalls Doxycycline Hyclate Tablets for Dissolution Failures
West-Ward Columbus Inc is recalling Doxycycline Hyclate 100 mg tablets because they failed to meet dissolution specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a situation where use of, or exposure to, a violative product may cause temporary or medically reversible health consequences. The failure to meet dissolution specifications is a quality issue that may affect efficacy but is not associated with acute severe injury or death in this context.
Plain-English summary
West-Ward Columbus Inc is voluntarily recalling Doxycycline Hyclate Tablets, USP, 100 mg. The recall involves 29,048 bottles, containing a total of 1,452,400 tablets. The product is identified by Lot# 71545B and has an expiry date of 01/19. The NDC number is 0143-2112-50.
The recall was initiated because the tablets failed to meet dissolution specifications. Dissolution is a critical quality attribute that ensures the drug releases properly in the body to provide the intended therapeutic effect. Failure to meet these specifications may result in the medication not working as intended.
The affected product was distributed nationwide in the USA. Consumers and healthcare providers should check their inventory for the specific lot number and expiry date listed above. If the product is found, it should be returned to the pharmacy or point of purchase for a refund or replacement. Patients should consult their healthcare provider for alternative treatment options if they have been prescribed this specific lot.
The recalled product
- Product
- DOXYCYCLINE HYCLATE (DOXYCYCLINE HYCLATE)
- Brand
- DOXYCYCLINE HYCLATE
- Manufacturer
- West-Ward Columbus Inc
- Category
- Drug — Antibiotic
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot# 71545B
- Expiry date: 01/19
UPCs (1)
- 0301432112508
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by West-Ward Columbus Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · DOXYCYCLINE HYCLATE
- Moderate
- ModerateAmerican Health Packaging Recalls Doxycycline Hyclate Tablets for Dissolution Failure
FDA (Drugs) · 2020-06-17
- ModerateHarvard Drug Group Recalls Doxycycline Hyclate Tablets for Dissolution Failure
FDA (Drugs) · 2020-06-10
- ModerateWest-Ward Recalls Doxycycline Hyclate Tablets Due to Dissolution Failure
FDA (Drugs) · 2020-06-03
- ModerateAmerican Health Packaging Recalls Doxycycline Hyclate Tablets for Dissolution Failure
FDA (Drugs) · 2019-08-07
Same manufacturer · West-Ward Columbus Inc
See all →- ModerateMethadone Hydrochloride Tablets recalled for illegible product identification
FDA (Drugs) · 2025-01-15
- LowMethotrexate Sodium tablets recalled due to illegible markings and unsmooth surface
FDA (Drugs) · 2023-11-01
- LowWest-Ward Recalls Leucovorin Calcium Tablets With Incorrect Identification Code
FDA (Drugs) · 2020-08-19
- ModerateWest-Ward Recalls Ethacrynic Acid Tablets for Impurity Failures
FDA (Drugs) · 2020-05-27
- SevereWest-Ward Recalls Oxcarbazepine Oral Suspension Due to Impurity Failures
FDA (Drugs) · 2019-09-25
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17